在转移型2型 papillary 细胞癌中使用toripalimab和lenvatinib进行组合治疗:一个病例报告
Wende Wang1, Minna Chen1, Wenwu Xue1
1The Department of Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China.
Frontiers in immunology
|November 24, 2025
概括
转移性2型 papillary 细胞癌 (PRCC) 是具有侵略性的. 与托利帕利马布 (抗PD-1) 和伦瓦提尼布的联合治疗显示,在患有转移性PRCC的患者中,持续的临床益处和耐受性.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 细胞癌研究 细胞癌研究
背景情况:
- 2型乳头性细胞癌 (PRCC) 是细胞癌 (RCC) 的一种侵袭性亚型.
- 诊断转移性PRCC可能是具有挑战性的,通常以肺部质量呈现.
- 一般来说,PRCC的预后很差,因此需要有效的治疗策略.
研究的目的:
- 报告一种转移型2型PRCC病例.
- 评估一线toripalimab和lenvatinib联合治疗的疗效和耐受性.
- 在一个具有挑战性的案例中突出显示持续的临床益处.
主要方法:
- 一名73岁的男性患者患有肺部质量,最初被误诊为原发性肺癌.
- 通过免疫组织化学的多学科再评估证实了转移型2型PRCC.
- 用托里帕利马布 (抗PD-1) 和伦瓦提尼布 (多酶抑制剂) 治疗11个月.
主要成果:
- 连续成像显示了部分反应 (PR).
- 观察到肺转移,淋巴腺病和阻塞性肺炎的显著回归.
- 组合疗法被很好地容忍,没有严重的不良事件.
结论:
- 托里帕利马布-伦瓦提尼布联合治疗显示出对转移型2型PRCC的潜在疗效和耐受性.
- 在具有挑战性的病例中,这种方法可能会提供持续的临床益处.
- 需要进一步的临床试验来验证这种治疗策略.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.2K
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
11.0K
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
